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The uncertainty of tuberculosis diagnosis
Tuberculosis is estimated to affect 10 million people 
each year, but this statistic is remarkably uncertain: 30% 
are countries’ estimates of undiagnosed, untreated, or 
unreported cases. Furthermore, about half of tuber­
culosis diagnoses globally are uncertain because they 
rely entirely on the non­specific clinical features of 
tuberculosis, without any laboratory confirmation.1
Laboratory tests for tuberculosis generally perform 
poorly and are scarcely available in resource­constrained 
settings where most cases of tuberculosis occur.1 
Consequently, when assessing a patient who is unwell 
with symptoms such as prolonged productive cough 
for whom rapid laboratory tests for tuberculosis are 
unavailable or negative, it is often difficult to discern 
whether the patient has tuberculosis or a more common 
disease such as a bacterial pneumonia. In this situation, 
some guidelines recommend a trial of antibiotics, 
a widely practiced approach entailing a few days of 
broad­spectrum antibiotics that are inactive against 
tuberculosis. This approach assumes that symptom 
persistence despite a trial of antibiotics implies that 
tuberculosis is probable, and that improvement on a 
trial of antibiotics rules out tuberculosis.2 However, these 
assumptions have been the subject of remarkably little 
research and are undermined by issues such as antibiotic 
resistance and the placebo effect.
In a systematic review and meta­analysis in 
The Lancet Infectious Diseases, Titus Divala and 
colleagues3 evaluated a trial of antibiotics as if it were 
a diagnostic test for tuberculosis. After screening 
9410 publications, they identified eight studies in which 
patients with initially negative rapid tuberculosis tests 
were treated with a trial of antibiotics, the response 
to which was compared with the subsequent results 
of more sensitive laboratory testing for tuberculosis. 
Of the 2786 patients who had a trial of antibiotics, 
overall 608 patients (22% [range 4–65]) were later 
found to have laboratory­proven tuberculosis. The 
crude results of these eight studies are summarised 
in the figure, which shows that whether patients’ 
symptoms persisted on a trial of antibiotics did 
not usefully predict laboratory­proven tuberculosis. 
For example, overall, 1307 (47% [range 6–76]) of 
2786 patients had symptoms that persisted despite a 
trial of antibiotics, implying that they had tuberculosis, 
but remarkably only 454 (35% [range 11–84]) of 
1307 patients with persistent symptoms were 
later found to have laboratory­confirmed tuberculosis. 
Furthermore, 154 patients (25% [range 3–85]) of 
608 patients later found to have laboratory­confirmed 
tuberculosis paradoxically improved on a trial of anti­
biotics, an improvement that should have ruled out 
this tuberculosis diagnosis. These crude percentages 
are complementary to the  rigorous random effects 
meta­analysis reported by Divala and colleagues, 
which suggested that a trial of antibiotics had pooled 
sensitivity of 67% (95% CI 42–85) and specificity of 
73% (58–85) versus mycobacteriology tests. This poor 
performance of a trial of antibiotics has important 
implications for policy and practice.3
The methods and results of these eight studies varied 
so greatly that the combined statistics and pooled 
meta­analyses have questionable precision.4 Despite this 
variability, the trial of antibiotics performed poorly for 
ruling tuberculosis in or out in each of the eight studies. 
These findings are approximations because tuberculosis 
laboratory testing might be false positive,5 and because 
false­negative laboratory tests in patients who have 
tuberculosis are frequent.6 Furthermore, molecular 
testing was only included in the initial rapid testing 
in one of these eight studies,7 but it has since become 
Figure: Crude data from the eight studies analysed by Divala and colleagues,3 adapted from their figure 2
If the response to a trial of antibiotics reliably indicated whether a patient had tuberculosis, then almost all of the 
patients would have true­positive or true­negative responses, and few patients would have false­positive or 
false­negative responses. Labels above each bar are the crude percentages reported in each study. Thus, the bars 
for all studies combined indicate the crude sum of the data from each of the eight studies. n=number of patients 
receiving a trial of antibiotics for suspected tuberculosis.
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widely used for diagnosing tuberculosis.1 None of these 
issues are likely to challenge Divala and colleagues’ 
conclusion that a trial of antibiotics is unreliable for 
informing tuberculosis diagnosis.
Importantly, broad­spectrum antibiotics might still 
be necessary, not to inform tuberculosis diagnosis, 
but rather because the patient’s illness requires anti­
biotic treatment, ideally guided by laboratory testing.8 
However, there is compelling evidence that broad­
spectrum antibiotic therapy for patients with a 
suspected respiratory tract infection might often be 
safely withheld initially, potentially reducing the risk of 
side­effects and antibiotic resistance.9
Divala and colleagues’ findings show that a trial of 
antibiotics should not generally be used to decide 
whether to commence tuberculosis therapy in patients 
with negative, pending, or unavailable laboratory 
tests for tuberculosis. But what should health systems, 
clinicians, and patients do instead? When should 
empirical treatment be commenced rather than doing 
additional tests or waiting to see how the illness evolves? 
There is an urgent need for operational research to 
address this knowledge gap, which will depend on local 
epidemiology, the severity of the patient’s illness, and 
the availability of repeat and more accurate laboratory 
tests.
More than a century after Robert Koch identified 
Mycobacterium tuberculosis, why do policy and practice 
still often include non­evidence­based algorithms for 
people with tuberculosis? Why are we clarifying the 
poor diagnostic reliability of a trial­of­antibiotics for 
tuberculosis only after they have been used millions 
of times during several decades? Both questions are 
answered in part by the chronic severe underfunding of 
tuberculosis research.1,10 The coronavirus disease 2019 
(COVID­19) emergency and resultant socioeconomic 
crisis will inevitably worsen the global tuberculosis 
pandemic by increasing tuberculosis risk factors and 
social determinants, and challenging health systems and 
access to them. It is striking that long before mortality 
attributed to COVID­19 approaches 1·5 million—the 
number of deaths caused by tuberculosis each year—
there has been unprecedented investment in research 
that is rapidly defining how best to care for people with 
suspected COVID­19. This should be an inspiration to 
the fight for tuberculosis elimination. Similar urgency 
and investment are also desperately needed to inform 
improved care for people suspected of having the most 
frequent infectious cause of death, tuberculosis.
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